GlobeNewswire by notified

EPH European Property Holdings PLC Profit Warning – EPH expects a Loss for the 1HY 2022 compared to a Profit in the previous year

Share

12September 2022, Nicosia, Cyprus I Ad hoc announcement pursuant to Art. 53 LR

EPH European Property Holdings PLC (“EPH”, the “Company”) would like to announce that the Company excepts a loss between 30 – 40 million for the first half year 2022, compared to a profit of 9 million for the same period a year earlier.

Consistent with our published outlook regarding the military conflict in the Ukraine published on 07 March 2022, market conditions have remained challenging. Sanctions imposed against and by Russia have changed the operating environment, particularly with regards to imports/exports, currency conversions, capital controls and operations of international companies. Although, EPH’s assets continue to operate independently as they did before, the Company expects a loss in the range of EUR 30-40 million compared to previous year. This result is driven by an impairment of the Russian portfolio - so far mainly due to the use of more conservative valuation assumptions to reflect the negative changes and uncertainty on the current market. However, the strong rouble appreciation against EUR offsets the losses from the fair value adjustment. The net asset value is therefore expected to increase from EUR 475 million to EUR 590-600 million.

The above stated figures in relation to the first half year 2022 are preliminary and are still subject to finalisation of the Company’s financials. The unaudited results for the period will be published by 30 September 2022. No further information on the Group’s business performance will be released until then.

_____________________________________________________________________________________________________

EPH European Property Holdings PLC is an investment company listed on SIX Swiss Exchange. Additional information on EPH European Property Holdings PLC is available by contacting Anna Bernhart Tel: +41 44 503 5400 or at contact@europeanpropertyholdings.com.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)19.4.2024 12:10:00 CEST | Press release

Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market the newly FDA approved high-concentration interchangeable biosimilar to Humira®The agreement broadens patient access and further commitment to availability of vital biologics in the U.S. and globally Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryvk in the U.S. market, the newly U.S. Food and Drug Administration (FDA) approved high-concentration interchangeable biosimilar to Humira. “This new partnership agreement supports our financial guidance and reflects Alvotech’s strong commitment to increasing patient access to more affordable healthcare,” said Robert Wessman, Chairman and CEO of Alvotech. The current multi-product commercialization partnership between T

Vaccinologists Keith Klugman and Shabir Madhi Awarded Sabin’s Prestigious Gold Medal; Infectious Diseases Epidemiologist Nicole Basta Receives Rising Star Award19.4.2024 12:00:00 CEST | Press release

WASHINGTON, April 19, 2024 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute yesterday presented the Albert B. Sabin Gold Medal to physician-researchers Keith Paul Klugman and Shabir Ahmed Madhi, and its Rising Star award to infectious diseases epidemiologist Nicole Elaine Basta at a ceremony in the National Academy of Sciences building in Washington D.C. Klugman and Madhi received the Sabin Gold Medal, one of the highest recognitions for vaccinologists globally, for their seminal combined contributions to the development of vaccines against pneumonia and diarrheal disease – major causes of death in children in low- and middle-income countries (LMICs). Klugman first met his then-graduate student Madhi at South Africa’s University of the Witwatersrand (also known as Wits University), where Klugman established, and Madhi expanded, a now globally renowned infectious diseases research institute. Apart from pneumonia, their work focused on maternal and children’s vaccines including influenza,

Forløb af ordinær generalforsamling 202419.4.2024 11:59:58 CEST | pressemeddelelse

Investeringsforeningen Investin har i dag afholdt ordinær generalforsamling i henhold til tidligere offentliggjort dagsorden. Ledelsens beretning og årsrapporten for 2023, herunder de i januar 2024 udbetalte udlodninger samt bestyrelsens honorar for 2023 blev godkendt af generalforsamlingen. Alle de af bestyrelsen stillede forslag blev vedtaget, herunder overflytning af afdeling I&T Nordiske Aktier Large Cap og afdeling I&T Globale Aktier ESG Select samt vedtægtsændringer. Til bestyrelsen genvalgtes Kim Høibye, Jesper Lau Hansen, Henrik Vincents Johansen samt Tine Roed, og bestyrelsen konstituerede sig efterfølgende med Kim Høibye som formand. Som revisor for foreningen genvalgtes EY Godkendt Revisionspartnerselskab. Eventuelle henvendelser vedrørende denne meddelelse kan rettes til direktør Tage Fabrin-Brasted på tlf. 44 55 91 60. Med venlig hilsen Investeringsforeningen Investin Tage Fabrin-Brasted Direktør

Investeringsforeningen ValueInvest Danmark – Prospektopdatering19.4.2024 11:32:00 CEST | pressemeddelelse

Opdateret prospekt for Investeringsforeningen ValueInvest Danmark offentliggøres dags dato. Der er fore­taget følgende opdateringer i prospektet: Indsættelse af regnskabstal for 2023 Prospektet er vedhæftet denne fondsbørsmeddelelse og kan endvidere downloades på www.valueinvest.dk eller rekvireres ved henvendelse til BI Management A/S, Bredgade 40, 1260 København K, tlf. 77 30 90 00. Med venlig hilsen BI Management A/S Martin Fjordlund Smidt Direktør Vedhæftet fil Prospekt IF ValueInvest Danmark 2024.04.19 FINAL clean inkl. bilag

Forløb af ordinær generalforsamling i Investeringsforeningen ValueInvest Danmark den 19. april 202419.4.2024 11:30:00 CEST | pressemeddelelse

Bestyrelsens beretning Bestyrelsens beretning blev taget til efterretning. Årsrapport, udbytte og bestyrelsesmedlemmernes honorar Årsrapporten for 2023 blev enstemmigt godkendt, herunder bestyrelsens honorar samt forslag om udbetaling af udbytte på 13,60 kr. pr. bevis for andelsklasse A i ValueInvest Global KL, og udbytte på 14,60 kr. pr. bevis for andelsklasse W i ValueInvest Global KL. Udbyttebetalingen til investorerne er foretaget aconto den 5. februar 2024. Forslag fremsat af bestyrelsen Der blev ikke fremsat forslag under dette punkt. Valg til bestyrelsen Bestyrelsen havde indstillet til genvalg af Ole Steffensen, Jens Harck og Bent Erik Carlsen, der enstemmigt blev valgt som medlemmer af bestyrelsen. Valg af revisor EY Godkendt Revisionspartnerselskab blev genvalgt som revisor. Med venlig hilsen Bestyrelsen for Investeringsforeningen ValueInvest Danmark c/o BI Management A/S Bredgade 40 1260 København K

HiddenA line styled icon from Orion Icon Library.Eye